Trials / Completed
CompletedNCT06603090
Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season
Text4Vax: Understanding the Effectiveness and Implementation of Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-2025 Season
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 66,147 (actual)
- Sponsor
- Columbia University · Academic / Other
- Sex
- All
- Age
- 6 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
This multi-site study assesses the impact of text message reminders on the receipt of COVID-19 and influenza text message reminders takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) network.
Detailed description
The study is to be conducted over the 1st season (September 2024-April 2025) as an effectiveness trial and the 2nd (September 2025-April 2026) as a replication study. This protocol covers the first season. Parents of eligible children who are 6 month-17 year-old who are due for both a COVID-19 and influenza vaccine will be sent text messages. Within each practice site, parents of eligible children will be randomized to receive either: 1) combined COVID-19 and influenza vaccine text message reminders, 2) COVID-19 reminders alone, 3) influenza reminders alone, or 4) no reminders (usual care). Randomization is to be stratified by practice site, age group and prior year's COVID-19/influenza vaccine history. Messages will be sent centrally and managed by the research team.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Text message influenza vaccine reminders | Text message influenza vaccine reminders |
| BEHAVIORAL | Text message COVID-19 vaccine reminders | Text message COVID-19 vaccine reminders |
| BEHAVIORAL | Text message influenza and COVID-19 vaccine reminders | Text message influenza and COVID-19 vaccine reminders |
Timeline
- Start date
- 2024-10-02
- Primary completion
- 2024-12-31
- Completion
- 2025-04-30
- First posted
- 2024-09-19
- Last updated
- 2025-07-11
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06603090. Inclusion in this directory is not an endorsement.